Screener
MaxCyte MXCT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: MaxCyte’s 10-Q, filed August 13, 2026. Open the filing →
- Filed
- Aug 13, 2026, 4:32 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-095971
FAQ
- What is MaxCyte's EPS (diluted)?
- MaxCyte (MXCT) reported EPS (diluted) of -$0.08 in Q2 2026.
- How has MaxCyte's EPS (diluted) changed year-over-year?
- MaxCyte's EPS (diluted) increased by 33.3% year-over-year, from -$0.12 to -$0.08.
- What is the long-term trend for MaxCyte's EPS (diluted)?
- Over 4 years (2021 to 2025), MaxCyte's EPS (diluted) has grown at a 18.2% compound annual growth rate (CAGR), from -$0.22 to -$0.43.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about MaxCyte's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude